The global gastroenterology market was valued at USD 31.13 billion in 2024 and is projected to grow at a CAGR of 5.80%, reaching USD 54.71 billion by 2034. The market growth is driven by the rising prevalence of gastrointestinal (GI) disorders, increasing geriatric population, and adoption of advanced diagnostic and therapeutic procedures. Additionally, growing awareness about digestive health, technological advancements in gastroenterology devices, and a focus on minimally invasive treatments are fueling market expansion.

Factors such as increasing incidence of Crohn’s disease, ulcerative colitis, gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) globally are further supporting the demand for specialized gastroenterology solutions.

Market Segmentation

By Disease Type:

Crohn’s Disease

Ulcerative Colitis

Gastroesophageal Reflux Disease (GERD)

Irritable Bowel Syndrome (IBS)

Others

By Treatment Type:

Devices

Therapeutics

Biologics/Biosimilars

Antacids

Laxatives

Antidiarrheal agents

Antiemetics

Antiulcer agents

Others

By Route of Administration:

Oral

Injectable

Others

By End User:

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Diagnostic Centers

Research and Academic Institutes

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Channels

By Region:

United States

United Kingdom

Germany

France

Italy

Spain

Japan

India

Leading Companies in the Gastroenterology Market

Major players driving growth and innovation include:

• Abbott

• Johnson & Johnson Services Inc.

• AbbVie Inc.

• Salix Pharmaceuticals

• GlaxoSmithKline Plc.

• Takeda Pharmaceutical Company Limited

• AstraZeneca plc

• Astellas Pharma US, Inc.

• Pfizer Inc.

These companies focus on developing advanced biologics, innovative devices, and targeted therapies to improve treatment outcomes for GI disorders.

Get a Free Sample Report with Table of Contents - www.expertmarketresearch.com/reports/gastroenterology-market/requestsample

Trends and Opportunities Shaping the Market

Rising GI Disorders: Increasing prevalence of Crohn’s disease, GERD, and IBS fuels demand.

Advanced Endoscopic Devices: Adoption of minimally invasive diagnostics and therapeutic procedures enhances patient care.

Biologics and Biosimilars: Expanding availability of biologic therapies improves disease management.

Aging Population: Growing geriatric population requires specialized gastroenterology care.

Digital and Telehealth Integration: Remote monitoring and AI-assisted diagnostics are improving treatment efficiency.

Emerging Markets: Rising healthcare infrastructure and awareness in countries like India and Japan provide growth opportunities.

The gastroenterology market is poised for strong growth through 2034, driven by increasing GI disorder prevalence, technological innovation, and expanding access to specialized treatments worldwide.